GRADE 3B FOLLICULAR LYMPHOMA
Clinical trials for GRADE 3B FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new GRADE 3B FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for GRADE 3B FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can booster drugs keep lymphoma in check after CAR t therapy?
Disease control Recruiting nowThis study tests whether adding two targeted drugs (mosunetuzumab and/or polatuzumab vedotin) after standard CAR T-cell therapy can help control lymphoma that has returned or not responded to treatment. About 396 adults with certain types of aggressive B-cell lymphoma will be ran…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 16, 2026 22:36 UTC
-
New drug combo aims to boost lymphoma treatment
Disease control Recruiting nowThis study tests whether adding three targeted antibodies (tafasitamab, retifanlimab, and rituximab) to standard chemotherapy can safely treat people with untreated diffuse large B-cell lymphoma. About 35 adults will receive the antibody combination before and during chemo. The g…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New dual-targeting CAR t therapy takes on hard-to-treat lymphoma in phase 3 trial
Disease control Recruiting nowThis phase 3 trial tests a new CAR T-cell therapy called rondecabtagene autoleucel (ronde-cel) that targets two proteins (CD19 and CD20) on lymphoma cells. It is compared to standard CD19-targeting CAR T-cell therapy in 400 patients with relapsed or refractory large B-cell lympho…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC
-
Double-targeted cell therapy takes on hard-to-treat lymphomas
Disease control Recruiting nowThis early-phase study tests a new type of immune cell therapy (CAR T cells) that targets two proteins, CD79b and CD19, on lymphoma cells. It is for people with non-Hodgkin lymphoma whose cancer has returned or stopped responding to standard treatments. The main goals are to chec…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated Jun 08, 2026 13:18 UTC
-
Hope for lymphoma patients: new drug cocktail targets resistant cancer
Disease control Recruiting nowThis study tests whether adding either tazemetostat or zanubrutinib to a standard two-drug therapy (tafasitamab and lenalidomide) can shrink tumors or delay cancer return in people with large B-cell lymphoma that came back or didn't respond to prior treatment. About 227 adults wh…
Matched conditions: GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 08, 2026 13:12 UTC